menu
    • menu
    [{"orgOrder":0,"company":"Kings College London","sponsor":"Epsilogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"MOv18 IgE","moa":"Folate receptor alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Kings College London","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kings College London \/ Epsilogen","highestDevelopmentStatusID":"6","companyTruncated":"Kings College London \/ Epsilogen"},{"orgOrder":0,"company":"Kings College London","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ibuprofen","moa":"COX","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Kings College London","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kings College London \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Kings College London \/ Not Applicable"},{"orgOrder":0,"company":"Kings College London","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ibuprofen","moa":"COX","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Kings College London","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Kings College London \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Kings College London \/ Not Applicable"},{"orgOrder":0,"company":"Kings College London","sponsor":"Marengo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"STAR0602","moa":"TCR-V beta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kings College London","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Kings College London \/ King\u2019s College","highestDevelopmentStatusID":"7","companyTruncated":"Kings College London \/ King\u2019s College"},{"orgOrder":0,"company":"Kings College London","sponsor":"Compass Pathways","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Kings College London","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Kings College London \/ King\u2019s College London","highestDevelopmentStatusID":"8","companyTruncated":"Kings College London \/ King\u2019s College London"}]

    Find Clinical Drug Pipeline Developments & Deals by Kings College London

    Menu

    Kings College London

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kings College London

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Kings College London

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Psilocybine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Recipient : Compass Pathways

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            COMPASS Pathways Launches Phase II Clinical Trial of Psilocybin Therapy in Anorexia Nervosa

                            Details : The phase II clinical trial will compare the effects of 25 mg and 1 mg of investigational COMP360 psilocybin when administered with psychological support, in 60 participants with anorexia nervosa

                            Brand Name : COMP360

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 28, 2022

                            Lead Product(s) : Psilocybine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Recipient : Compass Pathways

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kings College London

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Kings College London

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STAR0602

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Marengo Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Marengo Therapeutics and King’s College London Advance ImmunoOncology Research Collaboration

                            Details : STAR0602, is an antibody fusion molecule that binds and activates a specific Vβ TCR variant T cell subset while also delivering additional signals to the same T cell (known as cis-targeting) to further reprogram the T cell, to enhance anti-tumor activit...

                            Brand Name : STAR0602

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 08, 2021

                            Lead Product(s) : STAR0602

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Marengo Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Kings College London

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Kings College London

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ibuprofen

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kings College London Launches Trial Investigating the Effectiveness of Ibuprofen in COVID-19 Patients

                            Details : Trial to evaluate formulation of ibuprofen treatment for treating severe acute respiratory distress syndrome (ARDS), a complication of COVID-19, has launched in south London.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 02, 2020

                            Lead Product(s) : Ibuprofen

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Kings College London

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Kings College London

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MOv18 IgE

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Epsilogen

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Epsilogen Licences Experimental Ige Antibody from KCL

                            Details : The antibody developed at KCL in collaboration with Cancer Research UK is the first therapeutic IgE antibody to enter clinical trials.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 21, 2020

                            Lead Product(s) : MOv18 IgE

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Epsilogen

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Kings College London

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Kings College London

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ibuprofen

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            New study identifies drugs that are safe to use in COVID-19 treatment

                            Details : Study has found that there is no evidence for or against the use of non-steroidal anti-inflammatory drugs such as ibuprofen for patients with COVID-19.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 31, 2020

                            Lead Product(s) : Ibuprofen

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth